Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

Inclusion Criteria:

• Be in good health with the exception of renal impairment (RI) andhypercholesterolemia for participants in Panels A, B, and C. Participants with RIthat have stable, chronic medical or psychiatric conditions, including but notlimited to hypertension, hypercholesterolemia, diabetes mellitus, hyper- orhypothyroidism, gout, and chronic anxiety or depression may be included at thediscretion of the investigator

• Body Mass Index (BMI) ≥ 18 kg/m^2 and ≤ 40 kg/m^2, inclusive

• Be on a stable dose of any statin therapy defined as: no changes to dose or type ofstatin therapy for at least 2 months prior to Screening and participant anticipatesno changes to statin therapy throughout the study until the poststudy visit

Exclusion Criteria:

• History or presence of renal artery stenosis

• Had a functioning renal transplant in the past 5 years and is taking transplantmedication

• Participants in panels A, B and D: Has rapidly fluctuating renal function asdetermined by historical measurements

• Has a history gastrointestinal disease which might affect food and drug absorption,as determined by the investigator, or has had gastric bypass or similar surgery

• History of cancer (malignancy)

• History of significant multiple and/or severe allergies, or has had an anaphylacticreaction or significant intolerability to prescription or nonprescription drugs orfood

• Has received an anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) smallmolecule treatment, monoclonal antibody, or short interfering RNA (siRNA) or RNAinterference (ie, Inclisiran) within 12 months prior to Screening

• Participants with RI (Panels A, B, and C): Taking medications to treat chronicmedical conditions and/or conditions associated with renal disease, if participanthas not been on a stable regimen for at least 1 month (other than statins, whichrequire a stable dose for at least 2 months) prior to administration of the initialdose of study intervention, and/or is unable to withhold the use of themedication(s) within 4 hours prior to and 4 hours after administration of studyintervention

• Participated in another investigational study within 4 weeks prior to the prestudy (screening) visit

• Consumes greater than 3 servings of alcoholic beverages per day

• Consumes excessive amounts, defined as greater than 6 servings of caffeinatedbeverages per day